The United Kingdom and the United States have finalized a major bilateral deal that will keep zero tariffs on British medicine exports being sold in the US market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to raise spending on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that tariffs on these key exports will remain at nothing for a period of 36 months.
This deal comes after recent threats to hike import taxes on patented drug imports, with figures floated up to 100%.
"This deal with the United Kingdom strengthens the global environment for new treatments and brings long-overdue equity to American-British medicine commerce," a statement noted.
Trade Importance
Medicines are one of the the United Kingdom's biggest exports to the America, which is easily the largest buyer for large British pharmaceutical firms.
Trade data indicate that in the year to the end of last September, the UK sold drugs worth billions to the US. This value represented 17.4% of total UK exports in that span.
"This deal protects employment, stimulates funding and paves the way for the UK to emerge as a global hub for life sciences," a government official remarked.
Detailed NHS Changes
The deal includes several notable commitments from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to increase overall NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds exceeded twenty percent.
Recent Tensions
The pact comes amid a protracted dispute between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
This friction were heightened by assertions that American consumers were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been halted or scrapped, while substantial expansions have been pledged toward US facilities.
A senior figure publicly accepted that the NHS had to spend more on medicines, noting that its expenditure on drugs had declined as a proportion of its overall budget over the past decade.
